Cargando…

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars Erik, Alten, Rieke, Puig, Luis, Philipp, Sandra, Kvien, Tore K., Mangues, Maria Antonia, van den Hoogen, Frank, Pavelka, Karel, Vulto, Arnold G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182448/
https://www.ncbi.nlm.nih.gov/pubmed/30269270
http://dx.doi.org/10.1007/s40259-018-0306-1
_version_ 1783362566419906560
author Kristensen, Lars Erik
Alten, Rieke
Puig, Luis
Philipp, Sandra
Kvien, Tore K.
Mangues, Maria Antonia
van den Hoogen, Frank
Pavelka, Karel
Vulto, Arnold G.
author_facet Kristensen, Lars Erik
Alten, Rieke
Puig, Luis
Philipp, Sandra
Kvien, Tore K.
Mangues, Maria Antonia
van den Hoogen, Frank
Pavelka, Karel
Vulto, Arnold G.
author_sort Kristensen, Lars Erik
collection PubMed
description The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals’ understanding of biosimilars and utilising a managed switching programme.
format Online
Article
Text
id pubmed-6182448
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-61824482018-10-22 Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent Kristensen, Lars Erik Alten, Rieke Puig, Luis Philipp, Sandra Kvien, Tore K. Mangues, Maria Antonia van den Hoogen, Frank Pavelka, Karel Vulto, Arnold G. BioDrugs Current Opinion The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals’ understanding of biosimilars and utilising a managed switching programme. Springer International Publishing 2018-09-29 2018 /pmc/articles/PMC6182448/ /pubmed/30269270 http://dx.doi.org/10.1007/s40259-018-0306-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Current Opinion
Kristensen, Lars Erik
Alten, Rieke
Puig, Luis
Philipp, Sandra
Kvien, Tore K.
Mangues, Maria Antonia
van den Hoogen, Frank
Pavelka, Karel
Vulto, Arnold G.
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title_full Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title_fullStr Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title_full_unstemmed Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title_short Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
title_sort non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182448/
https://www.ncbi.nlm.nih.gov/pubmed/30269270
http://dx.doi.org/10.1007/s40259-018-0306-1
work_keys_str_mv AT kristensenlarserik nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT altenrieke nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT puigluis nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT philippsandra nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT kvientorek nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT manguesmariaantonia nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT vandenhoogenfrank nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT pavelkakarel nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent
AT vultoarnoldg nonpharmacologicaleffectsinswitchingmedicationthenoceboeffectinswitchingfromoriginatortobiosimilaragent